Androgens exacerbate motor asymmetry in male rats with unilateral 6-hydroxydopamine lesion

Hormones and Behavior

Volumn 60, Issue 5, 2011, Pages 617-624

  Cunningham, Rebecca L ^a,b   Macheda, Teresa ^b   Watts, Lora Talley ^c   Poteet, Ethan ^a   Singh, Meharvan ^a   Roberts, James L ^b   Giuffrida, Andrea ^b  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Aging; Gonadectomy; Motor function; Oxidative stress; Substantia nigra; Testosterone

Indexed keywords

OXIDOPAMINE; PLASMA ADVANCED OXIDATION PRODUCT; PROTEIN DERIVATIVE; TESTOSTERONE; UNCLASSIFIED DRUG;

AGE; AGED; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYLINDER TEST; DISEASE EXACERBATION; EXPERIMENTAL TEST; GONADECTOMY; HORMONE ACTION; MALE; MOTOR ASYMMETRY; MOTOR DYSFUNCTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; ROTATION TEST; TESTOSTERONE BLOOD LEVEL;

ADRENERGIC AGENTS; AMPHETAMINE; ANDROGENS; ANIMALS; DOPAMINERGIC NEURONS; MALE; MOTOR ACTIVITY; NEOSTRIATUM; ORCHIECTOMY; OXIDATIVE STRESS; OXIDOPAMINE; RATS; ROTATION; SUBSTANTIA NIGRA; TESTOSTERONE;

EID: 80555150661     PISSN: 0018506X     EISSN: 10956867     Source Type: Journal    
DOI: 10.1016/j.yhbeh.2011.08.012     Document Type: Article

References (99)

1. Adler A., Vescovo P., Robinson J.K., Kritzer M.F. Gonadectomy in adult life increases tyrosine hydroxylase immunoreactivity in the prefrontal cortex and decreases open field activity in male rats. Neuroscience 1999, 89:939-954.
2. Aksenova M.V., Aksenov M.Y., Carney J.M., Butterfield D.A. Protein oxidation and enzyme activity decline in old brown Norway rats are reduced by dietary restriction. Mech. Ageing Dev. 1998, 100:157-168.
3. Bains M., Cousins J.C., Roberts J.L. Neuroprotection by estrogen against MPP+-induced dopamine neuron death is mediated by ERalpha in primary cultures of mouse mesencephalon. Exp. Neurol. 2007, 204:767-776.
4. Beal M.F. Mitochondrial dysfunction in neurodegenerative diseases. Biochim. Biophys. Acta 1998, 1366:211-223.
5. Beatty W.W., Dodge A.M., Traylor K.L. Stereotyped behavior elicited by amphetamine in the rat: influences of the testes. Pharmacol. Biochem. Behav. 1982, 16:565-568.
6. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., Verna J.M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 2001, 65:135-172.
7. Calabrese V., Scapagnini G., Ravagna A., Colombrita C., Spadaro F., Butterfield D.A., Giuffrida Stella A.M. Increased expression of heat shock proteins in rat brain during aging: relationship with mitochondrial function and glutathione redox state. Mech. Ageing Dev. 2004, 125:325-335.
8. Camp D.M., Becker J.B., Robinson T.E. Sex differences in the effects of gonadectomy on amphetamine-induced rotational behavior in rats. Behav. Neural Biol. 1986, 46:491-495.
9. Cass W.A., Harned M.E., Bailey S.L. Enhanced effects of 6-hydroxydopamine on evoked overflow of striatal dopamine in aged rats. Brain Res. 2002, 938:29-37.
10. Cenci M.A., Lundblad M. Ratings of l-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr. Protoc. Neurosci. 2007, Chapter 9, Unit 9 25.
11. Creutz L.M., Kritzer M.F. Mesostriatal and mesolimbic projections of midbrain neurons immunoreactive for estrogen receptor beta or androgen receptors in rats. J. Comp. Neurol. 2004, 476:348-362.
12. Cunningham R.L., Giuffrida A., Roberts J.L. Androgens induce dopaminergic neurotoxicity via caspase-3-dependent activation of protein kinase Cδ. Endocrinology 2009, 150:5539-5548.
13. D'Astous M., Morissette M., Di Paolo T. Effect of estrogen receptor agonists treatment in MPTP mice: evidence of neuroprotection by an ER alpha agonist. Neuropharmacology 2004, 47:1180-1188.
14. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
15. Dawson T.M., Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003, 302:819-822.
16. Demirkiran M., Bozdemir H., Sarica Y. Vascular parkinsonism: a distinct, heterogeneous clinical entity. Acta Neurol. Scand. 2001, 104:63-67.
17. Deumens R., Blokland A., Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. 2002, 175:303-317.
18. Dietz V., Quintern J., Berger W. Electrophysiological studies of gait in spasticity and rigidity. Evidence that altered mechanical properties of muscle contribute to hypertonia. Brain 1981, 104:431-449.
19. Dluzen D.E. Effects of testosterone upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system of C57/B1 mice. Brain Res. 1996, 715:113-118.
20. Dluzen D.E., Ramirez V.D. Effects of orchidectomy on nigro-striatal dopaminergic function: behavioral and physiological evidence. J. Neuroendocrinol. 1989, 1:285-290.
21. Dluzen D.E., Green M.A., Ramirez V.D. The effect of hormonal condition on dose-dependent amphetamine-stimulated behaviors in the male rat. Horm. Behav. 1986, 20:1-6.
22. Edinger K.L., Frye C.A. Testosterone's anti-anxiety and analgesic effects may be due in part to actions of its 5alpha-reduced metabolites in the hippocampus. Psychoneuroendocrinology 2005, 30:418-430.
23. Ekue A., Boulanger J.F., Morissette M., Di Paolo T. Lack of effect of testosterone and dihydrotestosterone compared to 17beta-oestradiol in 1-methyl-4-phenyl-1,2,3,6, tetrahydropyridine-mice. J. Neuroendocrinol. 2002, 14:731-736.
24. Estrada M., Varshney A., Ehrlich B.E. Elevated testosterone induces apoptosis in neuronal cells. J. Biol. Chem. 2006, 281:25492-25501.
25. Fenelon G., Houeto J.L. Unilateral parkinsonism following a large infarct in the territory of the lenticulostriate arteries. Mov. Disord. 1997, 12:1086-1090.
26. Forno L.S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 1996, 55:259-272.
27. Friedman A., Kang U.J., Tatemichi T.K., Burke R.E. A case of parkinsonism following striatal lacunar infarction. J. Neurol. Neurosurg. Psychiatry 1986, 49:1087-1088.
28. Gavet O., Pines J. Progressive activation of CyclinB1-Cdk1 coordinates entry to mitosis. Dev. Cell 2010, 18:533-543.
29. Gavrielides M.V., Gonzalez-Guerrico A.M., Riobo N.A., Kazanietz M.G. Androgens regulate protein kinase Cdelta transcription and modulate its apoptotic function in prostate cancer cells. Cancer Res. 2006, 66:11792-11801.
30. Gavrilova N., Lindau S.T. Salivary sex hormone measurement in a national, population-based study of older adults. J. Gerontol. B Psychol. Sci. Soc. Sci. 2009, 64:i94-105. (Suppl 1).
31. Gille G., Hung S.T., Reichmann H., Rausch W.D. Oxidative stress to dopaminergic neurons as models of Parkinson's disease. Ann. N. Y. Acad. Sci. 2004, 1018:533-540.
32. Gillies G.E., Murray H.E., Dexter D., McArthur S. Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson's disease. Pharmacol. Biochem. Behav. 2004, 78:513-522.
33. Glick S.D., Jerussi T.P., Zimmerberg B. Behavioral and neuropharmacological correlates of nigrostriatal asymmetry in rats. Lateralization in the Nervous System 1977, 213-249. Academic Press, New York. S. Harnad (Ed.).
34. Hammond J., Le Q., Goodyer C., Gelfand M., Trifiro M., LeBlanc A. Testosterone-mediated neuroprotection through the androgen receptor in human primary neurons. J. Neurochem. 2001, 77:1319-1326.
35. Hanrott K., Gudmunsen L., O'Neill M.J., Wonnacott S. 6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta. J. Biol. Chem. 2006, 281:5373-5382.
36. Harding S.M., McGinnis M.Y. Effects of testosterone in the VMN on copulation, partner preference, and vocaliztions in male rats. Horm. Behav. 2003, 43:327-335.
37. Harman D. The aging process. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:7124-7128.
38. Heikkila R., Cohen G. Inhibition of biogenic amine uptake by hydrogen peroxide: a mechanism for toxic effects of 6-hydroxydopamine. Science 1971, 172:1257-1258.
39. Henze C., Earl C., Sautter J., Schmidt N., Themann C., Hartmann A., Oertel W.H. Reactive oxidative and nitrogen species in the nigrostriatal system following striatal 6-hydroxydopamine lesion in rats. Brain Res. 2005, 1052:97-104.
40. Heritage A.S., Stumpf W.E., Sar M., Grant L.D. (3-H)-dihydrotestosterone in catecholamine neurons of rat brain stem: combined localization by autoradiography and formaldehyde-induced fluorescence. J. Comp. Neurol. 1981, 200:289-307.
41. Hirsch E.C., Faucheux B., Damier P., Mouatt-Prigent A., Agid Y. Neuronal vulnerability in Parkinson's disease. J. Neural Transm. Suppl. 1997, 50:79-88.
42. Hofman A., Collette H.J., Bartelds A.I. Incidence and risk factors of Parkinson's disease in The Netherlands. Neuroepidemiology 1989, 8:296-299.
43. Hollander M., Koudstaal P.J., Bots M.L., Grobbee D.E., Hofman A., Breteler M.M. Incidence, risk, and case fatality of first ever stroke in the elderly population. The Rotterdam Study. J. Neurol. Neurosurg. Psychiatry 2003, 74:317-321.
44. Holmes D.J. F344BNF1 and BNF344F1 hybrid rats. Sci. Aging Knowl. Environ. 2004, as4.
45. Horner S., Niederkorn K., Ni X.S., Fischer R., Fazekas F., Schmidt R., Duft M., Augustin M., Homann N., Ott E. Evaluation of vascular risk factors in patients with Parkinson syndrome. Nervenarzt 1997, 68:967-971.
46. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 2003, 53(Suppl 3):S26-S36. discussion S36-8.
47. Johnson M.L., Day A.E., Ho C.C., Walker Q.D., Francis R., Kuhn C.M. Androgen decreases dopamine neurone survival in rat midbrain. J. Neuroendocrinol. 2010, 22:238-247.
48. Kalousova M., Zima T., Tesar V., Dusilova-Sulkova S., Skrha J. Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutat. Res. 2005, 579:37-46.
49. Kanthasamy A.G., Kitazawa M., Kaul S., Yang Y., Lahiri D.K., Anantharam V., Kanthasamy A. Proteolytic activation of proapoptotic kinase PKCdelta is regulated by overexpression of Bcl-2: implications for oxidative stress and environmental factors in Parkinson's disease. Ann. N. Y. Acad. Sci. 2003, 1010:683-686.
50. Kindlundh A.M., Lindblom J., Bergstrom L., Wikberg J.E., Nyberg F. The anabolic-androgenic steroid nandrolone decanoate affects the density of dopamine receptors in the male rat brain. Eur. J. Neurosci. 2001, 13:291-296.
51. Kirik D., Rosenblad C., Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 1998, 152:259-277.
52. Kritzer M.F. Selective colocalization of immunoreactivity for intracellular gonadal hormone receptors and tyrosine hydroxylase in the ventral tegmental area, substantia nigra, and retrorubral fields in the rat. J. Comp. Neurol. 1997, 379:247-260.
53. Kritzer M.F. Effects of acute and chronic gonadectomy on the catecholamine innervation of the cerebral cortex in adult male rats: insensitivity of axons immunoreactive for dopamine-beta-hydroxylase to gonadal steroids, and differential sensitivity of axons immunoreactive for tyrosine hydroxylase to ovarian and testicular hormones. J. Comp. Neurol. 2000, 427:617-633.
54. Kritzer M.F., Creutz L.M. Region and sex differences in constituent dopamine neurons and immunoreactivity for intracellular estrogen and androgen receptors in mesocortical projections in rats. J. Neurosci. 2008, 28:9525-9535.
55. Kritzer M.F., Brewer A., Montalmant F., Davenport M., Robinson J.K. Effects of gonadectomy on performance in operant tasks measuring prefrontal cortical function in adult male rats. Horm. Behav. 2007, 51:183-194.
56. Kulisevsky J., Berthier M.L., Avila A., Roig C. Unilateral parkinsonism and stereotyped movements following a right lenticular infarction. Mov. Disord. 1996, 11:752-754.
57. Kumar R., Agarwal A.K., Seth P.K. Free radical-generated neurotoxicity of 6-hydroxydopamine. J. Neurochem. 1995, 64:1703-1707.
58. Lewis C., Dluzen D.E. Testosterone enhances dopamine depletion by methamphetamine in male, but not female, mice. Neurosci. Lett. 2008, 448:130-133.
59. Li W., Poteet E., Xie L., Liu R., Wen Y., Yang S.H. Regulation of matrix metalloproteinase 2 by oligomeric amyloid beta protein. Brain Res. 2011, 1387:141-148.
60. Lotharius J., Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci. 2002, 3:932-942.
61. Luttge W. Endocrine control of mammalian sexual behavior: an analysis of the potential role of testosterone metabolites. Comprehensive Endocrinology. Endocrine Control of Sexual Behavior 1979, 341-364. Raven Press, New York. C. Beyer (Ed.).
62. Marshall J.F., Drew M.C., Neve K.A. Recovery of function after mesotelencephalic dopaminergic injury in senescence. Brain Res. 1983, 259:249-260.
63. Mayeux R., Marder K., Cote L.J., Denaro J., Hemenegildo N., Mejia H., Tang M.X., Lantigua R., Wilder D., Gurland B., et al. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am. J. Epidemiol. 1995, 142:820-827.
64. Mazzio E.A., Reams R.R., Soliman K.F. The role of oxidative stress, impaired glycolysis and mitochondrial respiratory redox failure in the cytotoxic effects of 6-hydroxydopamine in vitro. Brain Res. 2004, 1004:29-44.
65. Mo J.Q., Hom D.G., Andersen J.K. Decreases in protective enzymes correlates with increased oxidative damage in the aging mouse brain. Mech. Ageing Dev. 1995, 81:73-82.
66. Moore K.E., Kelly P.H. Biochemical pharmacology of mesolimbic and mesocortical dopaminergic neurons. Psychopharmacology: A Generation of Progress 1978, 221-234. Academic Press, New York. M.A. Lipton (Ed.).
67. Morgese M.G., Cassano T., Gaetani S., Macheda T., Laconca L., Dipasquale P., Ferraro L., Antonelli T., Cuomo V., Giuffrida A. Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2. Neurochem. Int. 2009, 54:56-64.
68. Morissette M., Jourdain S., Al Sweidi S., Menniti F.S., Ramirez A.D., Di Paolo T. Role of estrogen receptors in neuroprotection by estradiol against MPTP toxicity. Neuropharmacology 2007, 52:1509-1520.
69. Mouradian M.M. Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology 2002, 58:179-185.
70. Murray H.E., Pillai A.V., McArthur S.R., Razvi N., Datla K.P., Dexter D.T., Gillies G.E. Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen in males and females. Neuroscience 2003, 116:213-222.
71. Murrow R.W., Schweiger G.D., Kepes J.J., Koller W.C. Parkinsonism due to a basal ganglia lacunar state: clinicopathologic correlation. Neurology 1990, 40:897-900.
72. Nguyen T.V., Yao M., Pike C.J. Androgens activate mitogen-activated protein kinase signaling: role in neuroprotection. J. Neurochem. 2005, 94:1639-1651.
73. Oishi T., Hasegawa E., Murai Y. Sulfhydryl drugs reduce neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. J. Neural Transm. Park. Dis. Dement. Sect. 1993, 6:45-52.
74. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998, Academic Press, New York.
75. Polidori M.C., Griffiths H.R., Mariani E., Mecocci P. Hallmarks of protein oxidative damage in neurodegenerative diseases: focus on Alzheimer's disease. Amino Acids 2007, 32:553-559.
76. Przedborski S., Kostic V., Jackson-Lewis V., Naini A.B., Simonetti S., Fahn S., Carlson E., Epstein C.J., Cadet J.L. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci. 1992, 12:1658-1667.
77. Ramsden M., Shin T.M., Pike C.J. Androgens modulate neuronal vulnerability to kainate lesion. Neuroscience 2003, 122:573-578.
78. Roselli C.E., Resko J.A. Aromatase activity in the rat brain: hormonal regulation and sex differences. J. Steroid Biochem. Mol. Biol. 1993, 44:499-508.
79. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994, 59:401-415.
80. Savageau M.M., Beatty W.W. Gonadectomy and sex differences in the behavioral responses to amphetamine and apomorphine of rats. Pharmacol. Biochem. Behav. 1981, 14:17-21.
81. Schallert T., Tillerson J.L. Intervention strategies for degeneration of dopamine neurons in Parkinsonism: optimizing behavioral assessment of outcome. Central Nervous System Diseases 1999, 131-151. Humana Press Inc., Totowa, NJ. D.F. Emerich (Ed.).
82. Schrag A., Ben-Shlomo Y., Quinn N.P. Cross sectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London. BMJ 2000, 321:21-22.
83. Shastry B.S. Neurodegenerative disorders of protein aggregation. Neurochem. Int. 2003, 43:1-7.
84. Shemisa K., Kunnathur V., Liu B., Salvaterra T.J., Dluzen D.E. Testosterone modulation of striatal dopamine output in orchidectomized mice. Synapse 2006, 60:347-353.
85. Smith M.P., Cass W.A. Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinson's disease. Neuroscience 2007, 144:1057-1066.
86. Soto-Otero R., Mendez-Alvarez E., Hermida-Ameijeiras A., Munoz-Patino A.M., Labandeira-Garcia J.L. Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J. Neurochem. 2000, 74:1605-1612.
87. Spangler E.L., Waggie K.S., Hengemihle J., Roberts D., Hess B., Ingram D.K. Behavioral assessment of aging in male Fischer 344 and brown Norway rat strains and their F1 hybrid. Neurobiol. Aging 1994, 15:319-328.
88. Stark A.K., Pakkenberg B. Histological changes of the dopaminergic nigrostriatal system in aging. Cell Tissue Res. 2004, 318:81-92.
89. Tamas A., Lubics A., Lengvari I., Reglodi D. Effects of age, gender, and gonadectomy on neurochemistry and behavior in animal models of Parkinson's disease. Endocrine 2006, 29:275-287.
90. Thanvi B., Lo N., Robinson T. Vascular Parkinsonism-an important cause of parkinsonism in older people. Age Ageing 2005, 34:114-119.
91. Tillerson J.L., Cohen A.D., Philhower J., Miller G.W., Zigmond M.J., Schallert T. Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine. J. Neurosci. 2001, 21:4427-4435.
92. Tolosa E.S., Santamaria J. Parkinsonism and basal ganglia infarcts. Neurology 1984, 34:1516-1518.
93. Tomas-Camardiel M., Sanchez-Hidalgo M.C., Sanchez del Pino M.J., Navarro A., Machado A., Cano J. Comparative study of the neuroprotective effect of dehydroepiandrosterone and 17beta-estradiol against 1-methyl-4-phenylpyridium toxicity on rat striatum. Neuroscience 2002, 109:569-584.
94. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. Suppl. 1971, 367:69-93.
95. Ungerstedt U. Functional dynamics of central monoamine pathways. The Neurosciences: Third Study Program 1974, 979-988. MIT Press, Cambridge, Mass. F.O. Schmitt, F.G. Worden (Eds.).
96. Van Den Eeden S., Tanner C., Bernstein A., Fross R., Leimpeter A., Bloch D., Nelson L. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol. 2003, 157:1015-1022.
97. van Zagten M., Lodder J., Kessels F. Gait disorder and parkinsonian signs in patients with stroke related to small deep infarcts and white matter lesions. Mov. Disord. 1998, 13:89-95.
98. Woodward C.J. A re-evaluation of the anabolic effect of testosterone in rats: interactions with gonadectomy, adrenalectomy and hypophysectomy. Acta Endocrinol. (Copenh) 1993, 128:473-477.
99. Zijlmans J.C., Daniel S.E., Hughes A.J., Revesz T., Lees A.J. Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov. Disord. 2004, 19:630-640.